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Protease Activated Receptor 4 as a
Novel Modulator of Regulatory T Cell
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Sim Lai Tung 1,2, Daniel McCluskey 1, Lesley A. Smyth 1,3, Robert I. Lechler 1,2†,
Anthony Dorling 1,2† and Giovanna Lombardi 1,2*†
1MRC Centre for Transplantation, Guy’s Hospital, King’s College London, London, United Kingdom, 2NIHR Biomedical
Research Centre, Guy’s Hospital, Guy’s & St Thomas’ NHS Foundation Trust, King’s College London, London,
United Kingdom, 3 School of Health, Sport and Bioscience, University of East London, London, United Kingdom
Regulatory T cells (Tregs) are a subpopulation of T cells that maintain immunological
tolerance. In inflammatory responses the function of Tregs is tightly controlled by
several factors including signaling through innate receptors such as Toll like receptors
and anaphylatoxin receptors allowing an effective immune response to be generated.
Protease-activated receptors (PARs) are another family of innate receptors expressed on
multiple cell types and involved in the pathogenesis of autoimmune disorders. Whether
proteases are able to directly modulate Treg function is unknown. Here, we show using
two complimentary approaches that signaling through PAR-4 influences the expression
of CD25, CD62L, and CD73, the suppressive capacity, and the stability of Tregs, via
phosphorylation of FoxO1 and negative regulation of PTEN and FoxP3. Taken together,
our results demonstrate an important role of PAR4 in tuning the function of Tregs and
open the possibility of targeting PAR4 to modulate immune responses.
Keywords: protease activated receptor 4 (PAR4), regulatory T cells (Tregs), immunoregulation, PI3K/Akt signaling
pathway, phosphatase and tensin homolog on chromosome 10 (PTEN), forkhead box protein O1 (FoxO1)
INTRODUCTION
Accumulated evidence suggests that both innate and adaptive immunity are involved in regulating
inflammatory responses in diverse diseases including infection, autoimmunity and transplant
rejection though precise mechanisms are still unclear (1). Tregs are immunosuppressive cells
that maintain tolerance to self and immune balance (2, 3), as well as promoting tolerance
toward alloantigens in a transplant setting (4, 5). Thymus-derived Tregs are characterized by a
constitutively high expression of CD25 and the master transcription factor FoxP3. Mice deficient
in FoxP3 exhibit systemic autoimmune disease and the Tregs have an impaired suppressive capacity
in vitro, highlighting the importance of FoxP3+ Tregs in vivo (6–8).
The function of Tregs is tightly controlled in vivo to ensure that self-tolerance is maintained
whilst protective immune responses can be elicited. Various molecular signals are capable of
manipulating the function of Tregs including signaling through innate receptors such as Toll
like receptors (TLRs) (9, 10) and anaphylatoxin receptors (C3aR/C5aR) (11, 12). Signaling
through these receptors downregulates FoxP3 expression which causes Tregs to adopt an
effector T cell function (13, 14), ultimately causing autoimmunity (15, 16), or transplant
rejection (17–19). The precise mechanisms behind how these signaling pathways alter the
function of Tregs are not fully understood, although recent studies have suggested PTEN
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is important. In Tregs, PTEN dephosphorylates Akt which
enhances the activity of the transcription factor FoxO1, resulting
in increased FoxP3 expression (20, 21).
Protease-activated receptors (PARs) are a family of innate
G-protein-coupled receptors which comprises four members;
PAR1, 2, 3, and 4 (22–25). PARs are expressed on a variety of
cell types (26) and their expression is dramatically increased
during infection, trauma and tissue necrosis (27–29). PARs are
activated by serine proteases which cleave an extracellular region
of the receptor, exposing an “internal ligand” which facilitates
signal transduction. The serine protease thrombin, an important
enzyme involved in hemostasis and thrombosis can activate PARs
1, 3, and 4 but the efficiency with which this is achieved differs
between PARs. Importantly, higher concentrations of thrombin
are required to activate PAR4 compared to PAR1 (25, 30).
Thrombin is an important modulator of inflammation. In
vivo administration of thrombin has been shown to induce
systemic autoimmunity (31) whilst inhibition of thrombin can
ameliorate collagen induced arthritis (32), suggesting that serine
proteases act as danger signals. Whilst some of the observed
impact of thrombin is mediated via thrombosis, there are
important lines of evidence to suggest that signaling through
PAR is a predominant mechanism. Specifically, in vivo PAR1
activation causes mice to develop inflammatory bowel disease
(IBD) whilst PAR1 inactivation or PAR1 deficiencies reduce
the severity of IBD (33). Our previous work has highlighted
the critical role that thrombin, acting predominantly through
PAR1, plays in various models of acute and chronic vascular
inflammation, being required for generation of local chemokine
gradients and recruitment of inflammatory leukocytes (34, 35)
and for production of growth factors involved in hyperplastic
vascular disease (36). Furthermore, in vivo activation of PAR4
leads to inflammation and exaggerates ischemia reperfusion
injury (37, 38). The immunoregulatory effects of PAR1 and
PAR4 have also been demonstrated in experiments where the
action of serine proteases was blocked by the administration
of protease inhibitors α1-antitrypsin (AAT) or anti-thrombin
III (ATIII). Treatment with AAT prevented allogeneic islet
transplant rejection and the development of experimental
autoimmune encephalomyelitis (EAE) and correlated with an
increase in the number of FoxP3+ cells in vivo (39, 40).
Similarly, ATIII administration prevented hyperacute lung
rejection and induced indefinite survival of heart allografts,
but only at a high dose (500 U/Kg) (41, 42). Finally, we have
previously demonstrated the immunoregulatory influence of
PAR2 signaling on antigen presenting cells and CD4T cells
in mouse models of inflammation (43). These studies suggest
that modulation of serine protease activity or PAR signaling
promotes immunoregulation via downstream signaling pathways
on multiple cell types.
In this study, we assessed whether the presence or absence of
signaling through PAR4 impacted Treg function and influenced
immunoregulation. We show that Tregs from mice deficient
in PAR4 or WT Tregs following treatment with a PAR4
antagonist, express higher levels of key regulatory molecules and
exhibit an enhanced suppressive capacity in vitro and in vivo.
Furthermore, we demonstrate that activation of PAR4 on murine
Tregs inhibits their function via Akt dependent phosphorylation
of the transcription factor FoxO1 which, in turn, negatively
regulates PTEN and FoxP3. Altogether, the data presented here
demonstrate that PAR4 signaling inhibits the function of Tregs
and suggest that targeting PAR4 on Tregs can be a novel
therapeutic strategy.
MATERIALS AND METHODS
Mice
WT C57BL/6 (WT), BALB/c and transgenic CD45.2+ C57BL/6
mice were purchased from Charles River. Transgenic CD45.1+
C57BL/6, CD45.2+Rag2−/− and PAR4−/−mice weremaintained
under sterile conditions (Biological Services Unit, New Hunt’s
House, King’s College London). Procedures were carried
out in accordance with all legal, ethical and institutional
requirements (PPL70/7302).
Treg Isolation and Culture
CD4+CD25+ T cells were enriched from the spleen and LNs of
WT C57BL/6 or PAR4ko mice either by cell sorting, or using
the Dynabeads Flowcomp murine CD4+CD25+ Treg cells kit
(44), as per manufacturer’s protocols (ThermoFisher Scientific,
Paisley, Renfrewshire, UK). The purity of CD4+CD25+ cells by
both methods were over 95% (Supplementary Figures 2A,B).
Enriched Tregs were stimulated using either plate-bound anti-
CD3 (2µg/mL, BD Biosciences, Franklin Lakes, NJ, USA) and
anti-CD28 (4µg/mL, R&D systems, Abingdon, Oxfordshire,
UK), for short-term cultures (3–6 days) or in suppression
assay in vitro (described below). All cells were cultured
in complete media consisting of RPMI-1640 supplemented
with 10% fetal calf serum, 100 U/mL penicillin, 100µg/mL
streptomycin, 2mM L-glutamine, 10mMHEPES and 50µM β2-
mercaptoethanol (all from ThermoFisher Scientific) and Treg
cultures were supplemented with 10 U/mL recombinant human
IL-2 (Proleukin-Novartis, Camberley, Surrey, UK).
Flow Cytometry and Cell Sorting
Cells were stained with fluorescently-conjugated antibodies
specific for CD19 (clone: 1D3), CD4 (clone: GK1.5), CD8 (clone:
53-6.7), CD25 (clone: PC61.5), FoxP3 (clone: FJK-16s), CTLA4
(clone: UC10-4B9), CD103 (clone: 2E7; all from ThermoFisher
Scientific); CD3 (clone: 145-2C), CD62L (clone: MEL-14),
CD73 (clone: TY/11.8), CD45.1 (clone: A20), CD45.2 (clone:
104; all from Biolegend, London, UK); Neuropilin-1 (R&D,
Minneapolis, MN, USA); pSTAT5 (Cell Signaling Technology,
Danvers, MA, USA) and PAR4 (Bioss Antibodies, Woburn,
MA, USA). Dead cells were excluded using LIVE/DEAD
Fixable Near-IR Dead Cell Stain Kit (ThermoFisher Scientific).
Intracellular staining of FoxP3 and CTLA4 was performed using
the FoxP3/Transcription Factor Staining Buffer kit (eBioscience,
Santa Clara, CA, USA). Cells were acquired and sorted using
LSRFortessa II and FACSAria II, respectively. Data were analyzed
using FlowJo 10 software (Tree Star, Ashland, OR, USA). For
detection of PAR4, Tregs were first stained for CD4 and CD25,
fixed/permeabilized and stained for PAR4 and analyzed by flow
cytometry. For detection of phosphorylated STAT5, Tregs were
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starved for 2 h at 37
◦
C before being cultured in the presence
of 20 U/mL IL-2 for 30min. Cultured cells were harvested and
fixed/permeabilized for 10min before being incubated with an
unconjugated pSTAT5 antibody followed by detection antibody
(anti-rabbit IgG-AF-488, ThermoFisher Scientific) and analyzed
by flow cytometry.
Detection of PAR4 Expression
Total RNA was isolated from Tregs using TRIzol R© Reagent,
as per manufacturer’s protocols (ThermoFisher Scientific), and
cDNA was subsequently generated using the GoScript Reverse
Transcription system (Promega UK, Southampton). PCR
reaction was performed using 2 µL cDNA (reflecting 0.2 µg total
RNA), 12.5 pmol of a forward (FWD) and reverse (REV) primer
and GoTaq R© Master Mixes (Promega) with the following the
cycling condition: denaturation at 95
◦
C (20 s), annealing at 60
◦
C
(45 s) and extension at 72
◦
C (20 s); 40 cycles. PAR4 expression
was examined with FWD 5′-GTACCAGGGGAAGCCATGAAG-
3′ and REV 5-TCATGAGCAGAATGGTGGATGG-3′
primers (MGI: 1298207) and 18S as a housekeeping gene
with FWD 5′-AGAAACGGCTACCACATCCA-3′ and
5′CCCTCCAATGGATCCTCGTT-3′ primers (GeneBank:
X56974). Amplified PCR products (195 bp for PAR4 and 158bp
for 18S) were visualized on 1.5% agarose gels.
In vitro Suppression Assay
The suppressive activity of Tregs was determined by measuring
their ability to inhibit PAR4ko CD4+CD25− responder T cells
(Tresps) proliferation upon co-culture with PAR4ko antigen
presenting cells (APCs). Tresps were isolated from the spleen
and LNs of PAR4−/− mice using the murine CD4+CD25+
Treg cells kit (ThermoFisher Scientific) as per manufacturer’s
protocols. Similarly, APCs were isolated from the spleen and LNs
of PAR4−/− C57BL/6 mice using a negative selection protocol
established in the lab (45) whereby T cells were labeled using
anti-CD4 and anti-CD8 antibodies (YTS-191 and YTS-169,
respectively) and removed using anti-rat IgG-coated beads and
a magnet.
Suppression assays were set up by co-culturing 0.5 × 105
WT Tresps with 1 × 105 WT APCs in the presence of 1µg/ml
anti-CD3ε antibody (ThermoFisher Scientific). WT or PAR4
−/−
Tregs were added to co-cultures such that desired Treg:Tresp
ratios were obtained.
In some assays where PAR4 on Tregs was blocked or
stimulated, WT Tregs were used and co-cultured with KO
Tresps at a 1:2 Treg:Tresp ratio in the presence of KO
APCs. Mouse PAR4 antagonist (trans-Cinnamoyl-Tyr-Pro-Gly-
Lys-Phe-NH2, tcY-NH2) or agonist (Ala-Tyr-Pro-Gly-Lys-Phe-
NH2, AY-NH2; Bio-Techne, Minneapolis, MN, USA) were used
at a concentration of 50µM and human α-thrombin (HTI;
Essex Junction, VT, USA) was used at concentrations from 10
to 200 nM. Thrombin inhibitor hirudin (200 nM; Sigma-Aldrich,
MO, USA) or protease inhibitor cocktail (0.1%; Sigma-Aldrich,
MO, USA) was also used.
Co-cultures were incubated at 37
◦
C (5% v/v CO2) for
72 h after which Tresp proliferation was measured. This was
accomplished either by CFSE dye dilution, where Tresps
were labeled with 0.5µM CFSE prior to co-culture, or by
3H-thymidine incorporation, where 1 µCi/well 3H-thymidine
(Perkin Elmer UK, Beaconsfield) was added for the last 18 h
of culture.
Cytokine Analysis
IL-2, IFNγ, IL-10, and TNFα production wasmeasured in culture
supernatants using a cytometric bead array (CBA, BD, Oxford,
Oxfordshire, UK), as per manufacturer’s protocols.
Western Blot
Tregs were isolated and incubated in complete RPMI medium
for 2 h at 37
◦
C prior to assays being performed. WT cells were
then stimulated with 50µM mouse PAR4 agonist for 15min at
37
◦
C. Alternatively, WT and PAR4ko Tregs were stimulated with
plate-bound anti-CD3 and anti-CD28 antibodies for various
time points at 37
◦
C. Cell lysates were prepared in RIPA Lysis
and Extraction buffer (ThermoFisher Scientific) with protease
inhibitor cocktail (Merck) and proteins were separated on
pre-casted 4–12% mini gels (ThermoFisher Scientific) before
being transferred to immunoblots. Blots were blocked in 5%
BSA and labeled with primary antibodies specific for p-Akt
(Ser473), Akt, p-FoxO1 (Thr24), PTEN, and β-actin followed
by secondary HRP-conjugated antibodies (Cell Signaling
Technology), according to manufacturer’s recommendations.
Results were quantified by densitometry.
Skin Transplantation
Rag2−/− mice were reconstituted with 4 × 105
CD45.1+CD4+CD25− Tresps± 2× 105 CD45.2+CD4+CD25+
Tregs by intravenous injection 1 day prior to transplantation.
Skin transplantation was then performed as previously described
(44). Briefly, BALB/c tail skin grafts were transplanted onto the
Rag2−/− mice and protected with a plaster cast for 7 days. Grafts
were then monitored every 2–3 days for signs of rejection which
was defined as >80% necrosis, assessed by visual inspection.
Histological analyses were performed by H&E staining on grafts
which were rejected or harvested at day 65 or day 135 post-
transplant using Olympus BX51 microscope. The proportion of
CD45.1+ and CD45.2+ FoxP3+ cells in the draining LNs was
analyzed by flow cytometry at day 115.
Statistics Analysis
Data are expressed as mean ± SEM and statistical significance
was determined using an unpaired two-tailed Student’s t-test or a
two-way ANOVA as stated. In transplant experiments, statistical
differences in the survival time of grafts was determined using a
log-rank test.
RESULTS
In the Absence of PAR4 Signaling Tregs
Express Higher Levels of CD25, CD73, and
CD62L Molecules and Are More Stable
To investigate whether the expression of PAR4 influences Treg
phenotype, function and stability, these cells were studied in mice
lacking PAR4 (PAR4ko) and compared with the same population
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in wild-type (WT) mice. The percentage of CD4+CD25+
T cells were analyzed in the spleen (Spln) and peripheral
lymph nodes (LNs) by flow cytometry (gating strategy shown
in Supplementary Figure 1A). PAR4ko mice had significantly
higher percentages of CD4+CD25+ T cells (p < 0.05 and p <
0.005, respectively; Figure 1A) with increased levels of CD25
expression (MFI) compared to WT Tregs (p < 0.005 and p <
0.0005, respectively; Figure 1B). Next, we extended our analysis
to other important markers knowing to influence Treg function.
By gating on the CD4+CD25+ T cells, we observed that the
percentages of Tregs expressing CD62L+ (p < 0.005 and p <
0.0005, respectively; Figure 1C and Supplementary Figure 1B)
but not CD73+ (Figure 1E and Supplementary Figure 1C) were
significantly higher in PAR4ko compared to WT mice. However,
when the expression levels of CD62L and CD73 were analyzed
on CD4+CD25+ T cells, they were both significantly higher
in PAR4ko compared to WT animals (p < 0.05, p < 0.005,
p < 0.0005, and p < 0.0001, respectively; Figures 1D,F). In
contrast, there were no significant differences in FoxP3, CTLA-
4, neuropilin+ and CD103+ expression on CD4+CD25+ T cells
betweenWT and PAR4komice (Supplementary Figures 1D–G).
Overall, these observations suggest that Tregs derived from mice
lacking PAR4 have an increased percentage and expression of
some of the molecules known to relate to the function of Tregs.
To further dissect the role of PAR4 in Tregs, these cells were
purified from the spleen LNs of WT and PAR4ko mice. The
percentage of purity achieved was between 95 and 98% and
all the T cells that were CD4+ and CD25+ were also FoxP3+
(Supplementary Figures 2A,B). The lack of expression of PAR4
on highly purified Tregs from PAR4ko mice was confirmed
by PCR and flow cytometry (Supplementary Figures 2C,D) as
well as on total CD4+ T cells (data not shown). Purified Tregs
(CD4+CD25+ T cells) were then activated in vitro with IL-
2 alone or with a combination of plate-bound anti-CD3/anti-
CD28 antibodies and IL-2. After 3 days of incubation, the levels
of expression of FoxP3 and CD25 were significantly higher on
purified Tregs derived fromPAR4komice compared toWTTregs
(p < 0.05, p < 0.005, p < 0.0005, and p < 0.0001, respectively;
Figure 2A). To confirm that the higher expression observed in
PAR4ko Tregs was due specifically to the lack of PAR4 in Tregs,
WT Tregs were activated with plate-bound anti-CD3/anti-CD28
antibodies and IL-2 but also in the presence of a PAR4 antagonist
(tcY-NH2; Antag). As shown in Figure 2A the levels of FoxP3
and CD25 expression on the purified Tregs were increased in the
presence of the PAR4 antagonist.
Next, the stability of FoxP3 expression on WT and PAR4ko
Tregs was analyzed. After 3 and 6 days of activation with anti-
CD3/CD28 and IL-2, the proportions of WT Tregs expressing
FoxP3 was reduced from 90± 0.8% at 3 days to 66± 2.4% by day
6, whereas FoxP3 wasmaintained in PAR4ko (94± 0.9% at 3 days
and 90 ± 1.4% at day 6) (p < 0.05 and p < 0.0005, respectively;
Figure 2B). Overall, these results highlight the positive impact
that the absence of PAR4 has on the phenotype and stability
of Tregs.
Finally, the cell viability of WT and PAR4ko Tregs were
analyzed using live/dead near-IR dead cell stain kit. After 3 and 6
days of activation with anti-CD3/CD28 and IL-2, PAR4ko Tregs
FIGURE 1 | Tregs from PAR4ko mice express higher levels of CD25, CD62L,
and CD73 molecules. Cells obtained from homogenized the spleen, peripheral
lymph nodes (pLN) and mesenteric lymph nodes (mLN) of C57BL/6 WT (filled
bars) and PAR4ko (open bars) mice were analyzed using flow cytometry. The
percentage of CD25+ cells in the CD4+ T cells (A) and within the
CD4+CD25+ T cells the percentages of CD62L and CD73 (C,E) are shown.
The MFI levels for the same populations of these cells in (A,C,E) are shown in
(B,D,F). Graphs represent mean ± SEM from six mice per group. Data were
analyzed by unpaired two-tailed t-test. *p < 0.05, **p < 0.005, ***p < 0.0005,
and ****p < 0.0001 when WT and PAR4ko Tregs were compared.
had significantly less dead cells compared to WT group (p <
0.005, Figure 2C) at day 3 and 6 after activation, suggesting a role
of PAR4 signaling in cell survival.
Tregs in the Absence of PAR4 Have an
Augmented Suppressive Capacity
Compared to WT Tregs in vitro
Next we investigated the impact of PAR4 on the suppressive
capacity of Tregs. Highly pure Tregs isolated from the spleen
and pLNs of WT and PAR4ko mice were co-cultured with
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FIGURE 2 | PAR4 signaling regulates stability and survival of Foxp3+ Tregs in
vitro. CD4+CD25+ Tregs were freshly isolated from spleen and pLNs of WT
(filled bars) and PAR4ko (open bars) mice. The Tregs were activated with
anti-CD3/anti-CD28 in the presence of IL-2 for 3 days and in some cases
PAR4 antagonist (Antag) was added to WT Tregs. The MFI levels of FoxP3 and
CD25 expression were analyzed by flow cytometry (A). Flow cytometry
assessment of FoxP3 and CD25 expression on Tregs activated by
anti-CD3/anti-CD28 in presence of IL-2 for 3 and 6 days (B). Flow cytometry
assessment of live Tregs activated by anti-CD3/anti-CD28 in presence of IL-2
for 3 and 6 days (C). The cells were stained with live/dead near-IR dead cell
stain kit. Graphs show mean ± SEM from four experiments. Data were
analyzed by unpaired two-way t-test. *p < 0.05, **p < 0.005, ***p < 0.0005,
and ****p < 0.0001 in comparison between WT and PAR4ko Tregs.
CFSE-labeled responder CD4+CD25− T cells (Tresps) and
splenic antigen-presenting cells (APCs) isolated from PAR4ko
mice in the presence of anti-CD3 antibody (45). Tregs from
PAR4ko mice were significantly more efficient at suppressing
the proliferation of Tresps compared to WT Tregs (p < 0.0001;
Figures 3A,B). To quantify the suppressive potency of Tregs,
the Treg:Tresp ratio required to suppress 50% of the Tresps
proliferation (IC50) was calculated (46). PAR4ko Tregs had an
IC50 value of 0.12 compared to 0.72 for WT Tregs (Figure 3B),
suggesting that PAR4ko Tregs were 6-fold more efficient at
suppressing Tresps proliferation compared to WT Tregs. The
same results were obtained when the inhibition of Tresps
proliferation was measured using thymidine incorporation
(Supplementary Figures 3A,B).
Furthermore, the analysis of the cytokines revealed that the
immunosuppressive cytokine IL-10 was present in significantly
higher quantities in the supernatants of the Treg:Tresp co-
cultures when the Tregs were derived from PAR4ko compared
to WT Tregs (p < 0.0001; Figure 3C) whereas the opposite was
observed for IL-2, IFNγ and TNFα (p < 0.0001; Figure 3D),
further supporting the superior immunomodulatory function of
PAR4ko Tregs compared to WT Tregs in vitro.
To further validate the influence of PAR4 on Treg function,
the suppressive ability ofWT Tregs was evaluated in the presence
of the PAR4 antagonist (Antag) tcY-NH2 or agonist (Ag) AY-
NH2 (30, 47). As predicted, the suppressive capacity of WT Tregs
was significantly enhanced in the presence of the antagonist (p
= 0.0013; Figures 4A,B). In contrast, activation through PAR4
by the PAR4 agonist decreased the suppressive ability of the WT
Tregs (p = 0.0136; Figures 4A,B). To confirm the specificity of
PAR4 antagonist, the suppression assays were set up with PAR4ko
Tregs in the absence or in the presence of the antagonist. No
significant effect on the suppressive capacity of PAR4ko Tregs was
observed (Supplementary Figures 4A,B).
To investigate which component in the culture medium was
binding to PAR4 and allowed signaling through this receptor
in vitro, we explored first whether thrombin, a natural ligand
for PAR4, was present in culture and was responsible for the
differences in the suppressive ability observed in the presence
or absence of a functional PAR4 on Tregs. The suppression
assays were performed with WT Tregs in the presence of highly
specific thrombin inhibitor hirudin (Hir, 200 nM) or protease
inhibitor cocktail (known to inhibit serine and cysteine proteases
as well as aminopeptidases; 0.1%). As shown in Figures 4C,D, the
presence of the protease inhibitor cocktail but not hirudin could
enhance the suppressive capacity of WT Tregs (p = 0.0066),
suggesting that an unidentified protease other than thrombin
was responsible for our observations. However, to confirm that
thrombin has an effect on the suppressive capacity of WT Tregs,
thrombin was titrated into the suppression assays as shown in
Figures 4E,F. The suppressive ability of WT Tregs was reduced
in a dose-dependent manner (p = 0.0074, p = 0.0051, and p =
0.0020, respectively) and this effect was completely abolished by
the addition of hirudin (p= 0.0011). These results are consistent
with the hypothesis that an endogenous protease is responsible
for the baseline activation of PAR4 on WT Tregs.
PAR4ko Tregs Have a Superior Suppressive
Capacity Compared to WT Tregs in vivo
Given our initial in vitro observations of the consequences
of PAR4 expression on the regulatory ability of Tregs, the
function of Tregs was assessed in vivo using an adoptive
transfer model combined with a fully MHC-mismatched
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FIGURE 3 | Absence of PAR4 leads to the enhanced suppressive capacity of Tregs. CD4+CD25+ Tregs from WT spleen and pLN were purified and co-cultured with
PAR4ko Tresps and APCs in the presence of anti-CD3 for 72 h. Representative histograms showing the CFSE dilutions of Tresps cultured alone (No Tregs) or with
different numbers of WT or PAR4ko Tregs (A). Pooled data showing the percentages of suppression of WT and PAR4ko Tregs [p < 0.0001; (B)]. IC50 values
representing the Treg:Tresps ratio required to achieve 50% suppression are shown for the PAR4ko (triangles) and WT (squares) Tregs. Graphs show mean ± SEM
from six experiments. Data were analyzed by two-way ANOVA to compare between these two Treg groups. CBA analysis of cytokines IL-10 [p < 0.0001; (C)] and
IL-2, IFNγ, and TNFα [p < 0.0001; (D)] in the supernatants obtained from six suppression assays. Graphs show mean ± SEM from four experiments. Data were
analyzed by two-way ANOVA to compare between these two Treg groups with a sequential dilution.
skin transplant model. Rag2−/− mice were reconstituted
with CD45.1+ Tresps with or without CD45.2+ WT or
PAR4ko Tregs (2:1 Tresp:Treg ratio) and then transplanted
with BALB/c tail skin grafts after 24 h (44). Skin grafts on
mice that received Tresps only were rejected with a mean
survival time (MST) of 19 days (blue dotted line, Figure 5A).
Compared to the Tresps only group, skin graft survival was
significantly prolonged (MST = 70 days; p = 0.0005) when
recipient mice received WT Tregs (red dotted line, Figure 5A),
while indefinite survival was achieved when PAR4ko Tregs
Frontiers in Immunology | www.frontiersin.org 6 June 2019 | Volume 10 | Article 1311
Peng et al. PAR4 Modulates Treg Function
FIGURE 4 | PAR4 signaling modulates the suppressive capacity of Tregs. CD4+CD25+ Tregs from WT spleen and pLN were freshly isolated. Representative
histograms (A) and pooled data (B) showing in vitro suppression of CFSE-labeled PAR4ko Tresps by WT Tregs (filled bar; in the ratio of 2 to 1) in the absence or
presence of a PAR4 antagonist (Antag; open bar) or agonist (Ag; dotted bar) in 72 h suppressive assays co-cultured with PAR4ko APCs and addition of anti-CD3.
Graphs show mean ± SEM from four experiments. Data were analyzed by unpaired two-way t-test. *p < 0.05 and **p < 0.01 in comparison between the Treg groups
without or with PAR4 antagonist or agonist, respectively. Representative histograms (C) and pooled data (D) showing in vitro suppression of CFSE-labeled PAR4ko
Tresps by WT Tregs (filled bar; in the ratio of 2 to 1) in the absence or presence of thrombin inhibitor hirudin (Hir; dotted bar) or protease inhibitor cocktail (open bar) in
72 h suppressive assays. Graphs show mean ± SEM from four experiments. Data were analyzed by unpaired two-way t-test. **p < 0.01 in comparison between the
Treg groups without or with the cocktail, respectively. Representative histograms (E) and pooled data (F) showing in vitro suppression of CFSE-labeled PAR4ko Tresps
by WT Tregs (in the ratio of 2 to 1) in the absence (filled bar) or presence of thrombin (Thr) in different concentrations without (dotted bars) or with Hir (open bars).
Graphs show mean ± SEM from four experiments. Data were analyzed by unpaired two-way t-test. **p < 0.01 in comparison between the WT Tregs without or with
thrombin.
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FIGURE 5 | PAR4ko Tregs promote indefinite skin allograft survival in vivo. BALB/c skin graft survival was assessed in recipients Rag2−/− mice in which CD45.1+
Tresps only (blue dotted line, n = 6) or at a ratio 2 to 1 with CD45.2+ WT (red dotted line, n = 6) or PAR4ko (black solid line, n = 6) Tregs were adoptively transferred.
(A) Survival graph of skin allografts. Data were analyzed by Log-rank test. p = 0.0005, when Tresps with WT (or PAR4ko) Tregs were compared to Tresps only groups;
p = 0.0179, comparison between WT and PAR4ko Treg groups. (B) Representative H&E staining of skin grafts from recipient mice receiving Tresps only (day 20) or
Tresps with WT or PAR4ko Tregs (d65), or from Tresps with PAR4ko Tregs (d135). Bar, 50µm. Flow cytometry analysis of CD45.1+ and CD45.2+ population (C) and
the CD25+FoxP3+ cells in the CD4+ gated population of CD45.2+ cells (D) in the draining lymph nodes of the recipients receiving WT or PAR4ko Treg cells
sacrificed at d115. Graphs show mean ± SEM from four mice per group. Data were analyzed by unpaired two-way t-test. **p < 0.01 ***p < 0.001 when WT and
PAR4ko Treg groups were compared.
were administered (MST > 135 days, black solid line,
Figure 5A; p= 0.0005).
The morphology and cellular infiltration of the skin grafts
was assessed histologically with H&E staining. Skin grafts from
mice that received Tresps alone showed a dramatic loss of
the skin architecture and an extensive cell infiltration at 20
days post-transplantation (Top left, Figure 5B). Conversely,
grafts of mice that received Tresps with WT or PAR4ko Tregs
displayed a healthier morphology and fewer infiltrated cells
in PAR4ko Treg group at 65 days post-transplantation (Top
right and bottom right, respectively, Figure 5B). Importantly,
the skin grafts from mice that received PAR4ko Tregs the
skin architecture was nearly normal and very few infiltrating
cells at 135 days post-transplantation (Bottom left, Figure 5B).
Furthermore, the analysis of the draining LNs 115 days
after transplantation revealed a fewer number of CD45.1+
CD4+CD25− (p = 0.0006; Figure 5C) and a higher number of
CD45.2+ CD4+CD25+FoxP3+ cells (p = 0.0071; Figure 5D) in
recipient mice that have received PAR4ko Tregs compared to
mice that received WT Tregs.
Altogether, these findings suggest that Tregs expressing PAR4
are less potent in promoting skin transplant survival, highlighting
a functional role for this receptor in Tregs in vivo.
PAR4 Signaling Negatively Regulates the
Activity of FoxO1 and STAT5 via Akt
Having shown that in the absence of PAR4, Tregs had
higher expression of functional markers, increased stability
and augmented suppressive abilities both in vitro and in
vivo, the mechanisms by which PAR4 regulates Treg function
were investigated. Previous studies have indicated that PAR4
engagement activates downstream PI3K/Akt signaling cascades
in platelets (47). In Tregs it has been reported that increased PI3K
signaling and downstream Akt phosphorylation (48) inhibited
FoxP3 expression through the downregulation of PTEN, a potent
negative regulator of PI3K (49, 50). Given this we hypothesized
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FIGURE 6 | PTEN and Akt/FoxO1 links PAR4 signaling to regulate downstream pathways in WT Treg cells. Freshly isolated WT CD4+ CD25+ Tregs were stimulated
with PAR4 agonist for 15min. The levels of pAkt in these cells were analyzed by Western blots (A) and quantified against total Akt (B). Graph shows mean ± SEM
from four experiments. Data were analyzed by unpaired two-way t-test. *p < 0.05 in comparison between WT and PAR4ko Tregs. The Tregs were also activated with
anti-CD3/anti-CD28 for varied time points, and the levels of pAkt and pFoxo1 analyzed in western blots (C) and quantified against beta-actin [(D,E), respectively].
Graphs show mean ± SEM from four experiments. Data were analyzed by two-way ANOVA. P = 0.0071 and p < 0.0005, compared between WT and PAR4ko Tregs.
The level of total PTEN in the Treg cells from WT and PAR4ko mice was analyzed in Western blots (F) and quantified against beta-actin (G). Graph shows mean ±
SEM from four experiments. Data were analyzed by unpaired two-way t-test. **p < 0.001 in comparison between WT and PAR4ko Tregs. The Tregs were also
activated with IL-2 for 30min and then the MFI levels of pSTAT5 were analyzed by flow cytometry (H) and the cumulative data (I). Graph shows mean ± SEM from
three experiments. Data were analyzed by unpaired two-way t-test. *p < 0.05 in comparison between WT and PAR4ko Tregs.
that PAR4 signaling might control FoxP3 expression by altering
the Akt and PTEN pathways.
Highly pure WT Tregs were stimulated with the PAR4 agonist
AY-NH2 (50µM) for 15min and phosphorylation of Akt was
measured by Western Blot (Figure 6A). Significantly higher
levels of Akt phosphorylation were observed in the presence of
the PAR4 agonist (p= 0.0267; Figure 6B), compared to controls,
confirming that PAR4 engagement indeed triggered activation of
the PI3K/Akt pathway. To further investigate the downstream
consequences of this pathway, WT and PAR4ko Tregs were
activated with plate-bound anti-CD3/CD28 antibodies and
the phosphorylation status of Akt and FoxO1 was analyzed
(Figure 6C). Significantly higher levels of pAkt and pFoxO1
were observed in WT Tregs compared to PAR4ko Tregs, with
maximum phosphorylation at 5 and 30min post-activation,
respectively (p = 0.0071 and p < 0.0005; Figures 6D,E,
respectively). Consistent with these findings, the levels of PTEN
were higher in PAR4ko Tregs compared toWTTregs (p= 0.0082;
Figures 6F,G).
STAT5 phosphorylation is another intracellular signaling
pathway that has been shown to directly regulate the expression
and stability of FoxP3 through binding to the FoxP3 promoter
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(51). To assess whether this pathway was affected by the absence
of PAR4, the phosphorylation of STAT5 was measured in WT
and PAR4ko Tregs following stimulation with 20 U/ml IL-2 for
30min, as previous studies have shown that IL-2 signaling is
required for Treg development and function (52, 53). PAR4ko
Tregs had higher level of pSTAT5 after activation compared to
WT Tregs (p = 0.0474, Figures 6H,I). Taken together, these
observations show that PAR4 mediated PI3K/Akt signaling leads
to inhibition of FoxO1, PTEN and STAT5 activities, resulting into
the functional defect observed in PAR4+ Tregs.
DISCUSSION
Our study demonstrates for the first time the inhibitory role
that signaling through PAR4 has on Treg function. PAR4-
deficient mice were shown to have higher percentages of Tregs
in the spleens, peripheral and mesenteric LNs and PAR4ko Tregs
expressed higher levels of CD25, CD62L and CD73 molecules
compared to WT Tregs. We demonstrated that PAR4ko Tregs
had an enhanced suppressive capacity compared to WT Tregs
in vitro and in vivo. These results obtained with the PAR4ko
Tregs were confirmed by using WT Tregs and an antagonist of
PAR4. Finally the enhanced function of Tregs in the absence of
PAR4 signaling was associated with reduced PAR4-medited Akt
phosphorylation and an increased activity of FoxO1 and PTEN.
The results presented here highlight the importance of PAR4
ligation for the function of Tregs and possibly other cells of the
adaptive immune system.
PAR4 was initially described as a secondary thrombin receptor
which was less sensitive to thrombin-mediated activation than
PAR1 (25). During blood coagulation, immune cells including
Tregs can be exposed to a wide range of thrombin concentrations,
from picomolar to micromolar levels of 0.8∼1.4µM (30, 54,
55). This vast range of thrombin concentrations can have
very different effects on the function of local cells. Our data
suggests that thrombin ligation of PAR4 can impair the function
of Tregs in a similar manner to how platelets are affected
by activation of PAR4 (55). Alternative serine proteases have
also been reported to activate PAR4, such as Cathepsin G,
which is released by neutrophils, and mannose-binding lectin-
associated serine protease-1, an initiator of the complement lectin
pathway (56, 57). Our data using peptide antagonists of PAR4
indicate that PAR4 is being activated in our experimental system.
However, the lack of any effect of the highly specific thrombin
inhibitor hirudin indicates thrombin is unlikely to be present
in our culture system. In contrast, the capacity of the protease
inhibitor cocktail to enhance Treg function suggests that an
endogenous, as yet unidentified ligand of PAR4 is present in our
experimental systems.
The increased immunoregulation and the presence of Tregs
observed in murine transplant (39, 41) and EAE models (40)
following high-dose ATIII or AAT treatment might be explained,
at least in part, by the action of serine proteases influencing Treg
function through signaling via PAR4. Furthermore, this suggests
a physiological mechanism by which serine proteases, secreted
systemically or locally, can impact Tregs or other immune cells.
Indeed, we and others have shown that PAR signaling (PAR1
and 2) can modulate antigen uptake, priming, DC-mediated T
cell activation and migration (43, 58, 59) further suggesting that
PAR4 signaling may play an important role in immune balance.
The stability of FoxP3 and the high levels of expression of
CD25 molecules are important elements in the maintenance of
Treg function and protection from autoimmune disease (6, 7,
60, 61). The observation that these molecules are more stable
or expressed at higher levels on WT Tregs treated with a PAR4
antagonist suggests that stimulation through PAR4 negatively
regulates the stability and function of Tregs. This conclusion is
further accentuated by the fact that PAR4-deficient Tregs express
higher levels of functional molecules such as CD73 and CD62L,
relative to WT Tregs.
The degradation of ATP, ADP and AMP to adenosine,
achieved through the expression of CD73 and CD39 (62), and the
subsequent interactions with the A2AR receptor, are important
mechanisms by which Tregs function (63, 64). PAR4 signaling
has been shown to inhibit adenosine signaling in a rat myocardial
ischemia/reperfusion injury model (65), further supporting a
negative effect of PAR4 signaling on Treg function.
CD62L expression is also important to determine suppressive
capacity of Tregs. The CD62L+ subpopulation of Tregs has
been shown to possess more potent suppressive and proliferative
capacity in vitro than the CD62L− (66) and only CD62L+ Tregs
delayed the development of diabetes in an adoptive transfer
model (67) and protected mice from acute GVHD (68). Our
data showing that PAR4ko Tregs have higher levels of CD62L
might imply a relationship between these previously documented
observations and PAR4 signaling. More importantly, CD62L,
together with CCR7, is a key homing receptor for Tregs to
drive their migration to the secondary lymphoid tissues to
suppress unwanted immune responses as well as acquire optimal
immune regulatory activities (69–71). Higher expression of
CD62L in PAR4ko Tregs, compared to WT Tregs, may provide
an explanation for the increased number of FoxP3+ Tregs we
detected in the peripheral lymphoid tissues of reconstituted
Rag2−/− mice.
Our findings also explored the possible mechanisms
underlying the impact of PAR4 on Treg function. Although
TCR/CD28-induced PI3K/Akt signaling is required for FoxP3
expression and Treg development, Akt activation is also
known to inhibit FoxP3 expression by phosphorylation of the
downstream transcription factor FoxO1 (20, 72) and mTOR1
(73, 74). The former is a positive regulator of FoxP3, the lipid
phosphatase PTEN and the homing receptors CD62L and
CCR7. We observed that stimulating WT Tregs with a PAR4
agonist induced phosphorylation of Akt which is in line with
what has been observed in platelets (75, 76). Furthermore,
PAR4-deficient Tregs had decreased levels of Akt activation,
increased FoxO1 activity and an increased level of total PTEN
compared to WT Tregs. Based on the evidence that FoxO1 is
a pivotal regulator of Treg function (72) and from the results
in our study, we propose that PAR4 signaling is a negative
regulator of Treg function. Moreover, signaling via CD25
activates STAT5 to maintain FoxP3 expression in Tregs (51)
and our data demonstrate that PAR4ko Tregs have increased
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FIGURE 7 | Possible underlying mechanism of PAR4 signaling. PAR4
activation may directly activate PI3K/AKT pathway, which then upregulates the
activity of the downstream effector mTOR and downregulates the activities of
Foxo1 and PTEN, and subsequently controls the expression of Foxp3, CD25,
and CD62L. However, accumulation of excessive proteases at the sites of
inflammation may overregulate PAR4 signaling on various cell types including
Tregs, which then reduces function, stability, and mobility of Tregs. Moreover,
PAR4 activation may also negatively control adenosine pathway. Once
removing PAR4 signaling, the negative regulator, these Tregs possess “super”
capacity with a Foxp3high CD25high CD62Lhigh phenotype and are able to
induce immune tolerance.
level of pSTAT5, suggesting a mechanism by which PAR4ko
Tregs have an enhanced stability of FoxP3 expression. In
summary, we propose that PAR4-mediated Akt activation
inhibits FoxO1 activity and consequently downregulates
FoxP3, PTEN, CD25, and CD62L expression. Additionally,
the interference with the adenosine and STAT5 pathways
caused by PAR4 signaling is also likely to influence the function
of Tregs (Figure 7).
Apart from TCR and IL-2 signaling pathways, PAR4 signaling
is also likely that can cross-talk with several other signaling
pathways. One possible candidate is TGF-beta as it plays a
crucial role in the in vitro induction of Tregs (iTregs) (77, 78).
However, in vitro TGFβ-induced FoxP3+ iTregs are lack of the
epigenetic (79–81) and transcriptional (82, 83) signature of in
vivo generated FoxP3+ Tregs, which is reflected by variable
suppressive capacity (84) and unstable FoxP3 expression (79, 81,
85). Whether this feature is associated with PAR4 signaling needs
further investigation.
In conclusion, our findings demonstrate a novel
immunoregulatory role for PAR4 signaling in controlling
the function of Tregs. It seems reasonable to speculate that
PAR4-mediated signaling constrains the function of Tregs
early in an inflammatory/immune response, thereby allowing
an effective response to be generated against a pathogen.
As inflammation subsides and PAR4 signaling diminishes,
Tregs regain their potency and ability to prevent unwanted
autoimmunity that might otherwise be triggered. Finally, the
unique functional features exhibited by PAR4ko Tregs suggest
that modulating PAR4 signaling in Tregs could have therapeutic
benefit in autoimmunity and cancer.
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